In addition, engraftment with PBMCs or CD34+ cells expanded from PBMCs has the disadvantage of a short life before the onset of GVHD [33] and the repertoire of human immune cells in the mouse is limited (over-representation of CD4+ T cells and few myeloid-derived cells) [14]. The gene discussed is CD34; the disease is graft versus host disease.